PATENT CLAIM ANALYSIS

Application Number: 15985541
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-01
Patent Classification: ["514", "013300"]

Abstract:
The present invention relates to fusion polypeptide compositions comprising immunoglobulin-type-2 binding domains of Vascular Endothelial Growth Factor Receptor, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.

Claim (Index 14):
The fusion polypeptide of  claim 13 , wherein said two or more VEGF receptor immunoglobulin-like-type 2 domains are at least two distinct human VEGF receptor immunoglobulin-like-type 2 domains.

Metadata:
- Claim Count in Document: 51.0
- Percentile: 93.0
- Lexical Diversity: 1.28205
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12727188', '11089803', '14336812', '11998709', '14768701']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.764609206314108
- 35 USC 102 Novelty (BERT): 0.5126388772159646
- Combined Prediction Score: 0.7394121734042938
- Mean Citation Score: 287.01060199999995
- Max Citation Score: 310.06473
- Similarity Product: 267.6732894708896

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test